Clinical Trial Detail

NCT ID NCT02572453
Title Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

anaplastic large cell lymphoma

diffuse large B-cell lymphoma

mantle cell lymphoma

Therapies

Onalespib

Age Groups: adult senior

Additional content available in CKB BOOST